schedule an appointment
Free Consultation 646-661-7615

Latisse Evaluations

LATISSE is an FDA-approved treatment to grow eyelashes for people with inadequate or not enough lashes.

Like the hair on your head, your eyelashes grow for a short time and then they eventually fall out. LATISSE addresses this issue by changing the growth phase of your eyelash hair cycle.  The active ingredient known as bimatoprost not only increases the number of hairs that grow, but it extends the growing phase allowing the eyelashes to stay around longer.

LATISSE received its initial U.S. approval in 2001. It is not a cosmetic device like mascara. This is a drug that requires a medical prescription and should be monitored by your eye doctor. While the FDA states this treatment is safe for most people, an ocular evaluation must occur to determine if you are a candidate.

Results are often seen within 1 to 2 months of use. After about 3 months of treatment our doctors may recommend a treatment schedule of once every 2 or 3 days. Be aware that not every doctor is familiar with LATISSE. The doctors at Compton Eye Associates have extensive experience with this product and can help you achieve the results you desire.


LATISSE (bimatoprost ophthalmic solution) 0.03% Important Information Indication

LATISSE (bimatoprost ophthalmic solution) 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth, including length, thickness, and darkness.


Important Safety Information

Warnings and Precautions: In patients using LUMIGAN (bimatoprost ophthalmic solution) or other prostaglandin analogs for the treatment of elevated intraocular pressure (IOP), the concomitant use of LATISSE may interfere with the desired reduction in IOP. Patients using prostaglandin analogs including LUMIGAN for IOP reduction should only use LATISSE after consulting with their physician and should be monitored for changes to their intraocular pressure.

Increased iris pigmentation has occurred when bimatoprost solution was administered. Patients should be advised about the potential for increased brown iris pigmentation, which is likely to be permanent.

Bimatoprost has been reported to cause pigment changes (darkening) to periorbital pigmented tissues and eyelashes. The pigmentation is expected to increase as long as bimatoprost is administered, but has been reported to be reversible upon discontinuation of bimatoprost in most patients.

There is the potential for hair growth to occur in areas where LATISSE solution comes in repeated contact with skin surfaces. Apply LATISSE only to the skin of the upper eyelid margin at the base of the eyelashes.

LATISSE solution should be used with caution in patients with active intraocular inflammation (eg, uveitis) because the inflammation may be exacerbated.

Adverse Reactions: The most frequently reported adverse events were eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye symptoms, and erythema of the eyelid. These events occurred in less than 4% of patients.

Postmarketing Experience: The following reactions have been identified during postmarketing use of LATISSE in clinical practice: burning sensation (eyelid), erythema periorbital, eye swelling, eyelid irritation, eyelid edema, eyelid pruritus, iris hyperpigmentation, lacrimation increased, madarosis and trichorrhexis (temporary loss of a few eyelashes to loss of sections of eyelashes, and temporary eyelash breakage, respectively), rash (including macular, erythematous, and pruritic limited to the eyelids and periorbital region), skin discoloration (periorbital), and vision blurred.

Use in Specific Populations: Use in pediatric patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation following long-term chronic use.